Deal in Russia could cause Pfizer, GSK to lose contracts

A unit of Rostec, Russia's state corporation, has inked a pact with the Serum Institute of India to locally produce several vaccines in Russia, the Pharma Letter reports, a development that could bring about "significant losses" for Pfizer ($PFE) and GlaxoSmithKline ($GSK) in the country. The publication cited a Rostec official as the source of the information, adding that the deal calls for local production of vaccines against polio, pneumococcus and Haemophilus influenzae as well as other medicines. Report (sub. req.)

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.